Prosecution Insights
Last updated: November 04, 2026

Inedita Bio Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Inedita Bio Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is under the review of 1 distinct examiner, SHARMA, SANTOSH. The portfolio is currently active in 1 distinct art unit, which provides a specific technical context for this biopharmaceutical filing. This focused activity ensures that the biotechnology claims are evaluated within the designated technical division. Practitioners should focus their strategy on the requirements of the assigned examiner and the standards of the 1 distinct art unit. The current data reflects a precise effort to secure intellectual property for a specific innovation.

SHARMA, SANTOSH is the busiest examiner. As there is only the 1 pending office action in total, this official manages the company's entire active prosecution effort. This concentrated workload means that the success of the company's current patent strategy is dependent on the interactions with this official. The presence of the action within the Biotechnology & Pharmaceuticals area suggests a rigorous examination process. Practitioners must ensure that their technical arguments are robust and specifically tailored to the nuances of the 1 distinct art unit involved. This arrangement allows for a direct communication channel between the applicant and the patent office to resolve the 1 pending office action. The 1 distinct examiner provides a singular point of review for the company's biotechnology claims.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHARMA, SANTOSH 1 73.3% +29.3%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18844880 METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT SHARMA, SANTOSH —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18844880 METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT SHARMA, SANTOSH —

Top Art Units

Art UnitApps
1663 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18844880 METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT SHARMA, SANTOSH 1663 §101§102§103§112 Non-Final OA — Pending Sep 06, 2024

Managing Inedita Bio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Inedita Bio Inc. have?

Inedita Bio Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Inedita Bio Inc. applications?

Santosh Sharma has the most, with 1 of Inedita Bio Inc.'s pending office actions.

What technology area are Inedita Bio Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month